Botulinum toxin type A inhibits rat pyloric myoelectrical activity and substance P release in vivo

2007 ◽  
Vol 85 (2) ◽  
pp. 209-214 ◽  
Author(s):  
Yi-Ping Hou ◽  
Yong-Ping Zhang ◽  
Yan-Feng Song ◽  
Chun-Min Zhu ◽  
Yin-Chun Wang ◽  
...  

The effect of botulinum toxin type A (BTX-A) on rat pyloric myoelectrical activity in vivo and the content and distribution of substance P (SP) in pylorus were investigated, respectively, with electromyography, radioimmunoassay, and immunohistochemistry. A pair of electrodes for recording pyloric myoelectrical activity and a guide cannula for drug injection were implanted into the pylorus. The changes of pyloric myoelectrical activity were recorded followed vehicle, 10, 20, and 40 U/kg body mass of BTX-A injection. Pyloric tissues were dissected for radioimmunoassay and immunohistochemistry after recording. The 3 dosages of BTX-A injections caused the reduction of slow wave of pyloric myoelectrical activity in amplitude but not in frequency and the diminishment of spike activity in amplitude and spike burst. The inhibitory effect of 20 U/kg BTX-A was significantly different from that of 10 U/kg (p < 0.05), but not from the effect of 40 U/kg administration (p > 0.05). After BTX-A intrasphincteric injection, SP content was reduced in the pylorus, and cell number of SP-immunoreactivity was decreased more in myenteric nerve plexus of circular muscle and in mucosa of pylori. In conclusion, BTX-A inhibits pyloric myoelectrical slow activity in amplitude and spike activity and weakens pyloric smooth muscle contractility depending on threshold of dose or concentration. BTX-A-induced inhibition of pyloric myoelectrical activity implies a mechanism of inhibiting SP release from the autonomic and enteric nervous terminals in the pylorus.

Neuroscience ◽  
2017 ◽  
Vol 358 ◽  
pp. 137-145 ◽  
Author(s):  
Ivica Matak ◽  
Valéria Tékus ◽  
Kata Bölcskei ◽  
Zdravko Lacković ◽  
Zsuzsanna Helyes

2020 ◽  
Vol 10 (1) ◽  
Author(s):  
Xuan Wang ◽  
Sheng Tian ◽  
Hansen Wang ◽  
Pan Liu ◽  
Heqing Zheng ◽  
...  

Abstract Background Botulinum toxin type A (BTX-A) was considered to be a new potential drug for neuropathic pain (NP) treatment. Results In vivo, BTX-A attenuated chronic compression injury (CCI)-induced pain in rats, and reduced production of pro-inflammatory factors. The inhibition of BTX-A to expression and phosphorylation of SNAP23 were partly reversed by TLR2/MyD88 upregulation. In LPS-stimulated microglia, we also found that BTX-A suppressed TLR2, MyD88, p-SNAP23 and SNAP23 expression, and reduced pro-inflammatory factors secretion. Upregulation of TLR2 and MyD88 recued the inhibition of BTX-A to LPS-induced activation of SNAP23. Then, we demonstrated that BTX-A reduced expression of SNAP23 through inhibition of IKKα/β phosphorylation. Besides, the inhibition of BTX-A to LPS-induced upregulation of SNAP23 can be reversed by proteasome inhibitor. NEDD4, an E3 ubiquitin ligase, was proved to be bind with SNAP23. BTX-A reduced expression of SNAP23 via facilitating ubiquitin-mediated degradation of SNAP23. Conclusion Overall, our data demonstrated that BTX-A attenuated NP via reducing the secretion of pro-inflammatory factors from microglia by inhibition of TLR2/MyD88 signaling. BTX-A downregulated expression of SNAP23 via reducing phosphorylation of IKKα/β, and enhancing ubiquitination of SNAP23 by suppressing TLR2/MyD88 signaling.


Toxins ◽  
2015 ◽  
Vol 7 (10) ◽  
pp. 4143-4156 ◽  
Author(s):  
Yu-Feng Shao ◽  
Jun-Fan Xie ◽  
Yin-Xiang Ren ◽  
Can Wang ◽  
Xiang-Pan Kong ◽  
...  

2006 ◽  
Vol 175 (4S) ◽  
pp. 92-93 ◽  
Author(s):  
Alvaro Lucioni ◽  
Gregory T. Bales ◽  
Katherine W. Turk ◽  
Tamara Lotan ◽  
Sean P. Cook ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document